Dicerna Pharmaceuticals, Inc. (DRNA) and Novo Nordisk (NVO) have signed an agreement under which Novo Nordisk will acquire Dicerna for $3.
Novo Nordisk (NYSE:NVO) announced new phase 3b trial (DUAL VII) results with Xultophy® (IDegLira). Xultophy®is a once-daily, single injection fixed combination of a …
Novo Nordisk A/S (ADR) (NYSE:NVO) announced that the company is investing 500 million Danish kroner in a new 19,000 m2 warehouse in Hillerød, …
When I read all these articles about investing strategies and look at the moves from big gurus, I see Europe as a dominant …
Novo Nordisk was established in 1989 as a merger of two of the oldest insulin companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium founded …
